Catalyst ligands

2083-68-3, Trimethyloctylammonium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: In these experiments, quaternary ammonium bromides with C8-C18alkane chains were used as precursors of theophylline-based ILs (TILs).Octyltrimethylammonium bromide and decyltrimethylammoniumbromide were obtained from Fluka (Ronkonkoma, NY, USA).Dodecyltrimethylammonium bromide, tetradecyltrimethylammoniumbromide, and hexadecyltrimethylammonium bromide were obtainedfrom Acros Organics. Octadecyltrimethylammonium bromide wasobtained from Sigma-Aldrich (St. Louis, MO, USA). All chemicals were ofanalytical grade. The TILs were synthesized as described previously [10].Briefly, 0.05 mol of alkyltrimethylammonium bromide was dissolved inmethanol and stoichiometric amount of potassium hydroxide in methanolwas added. The solution was stirred for 5 min at 25 C and filteredin order to remove precipitated KBr. Next, the stoichiometric amount oftheophylline in substantia was added. The obtained solution was stirredfor 15 min, filtered again and the solvent was evaporated using rotaryevaporator. The product was dissolved in acetone and filtered to removeresidual KBr. Then, the acetone was evaporated and the product wasdried. The purity and concentration of obtained products in water solutionduring the next experiments were determined by UV spectroscopy(G10S UV-Vis, Thermo Fisher Scientific, Madison, WI, USA) using thecalibration curve. The investigated ILs exhibit a characteristic peak at lambda=269 nm. The theophylline-based ILs were designated as C8T-C18T dependingon the number of carbon atoms in the alkyl chain.

2083-68-3, As the paragraph descriping shows that 2083-68-3 is playing an increasingly important role.

Reference£º
Article; Borkowski, Andrzej; Kowalczyk, Pawe?; Czerwonka, Grzegorz; Cie?la, Jolanta; C?apa, Tomasz; Misiewicz, Anna; Szala, Mateusz; Drabik, Marcin; Journal of Molecular Liquids; vol. 246; (2017); p. 282 – 289;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4479-74-7, 2,2-Bipyridine-6,6-dicarboxylic Acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of Gd(NO3)3¡¤6H2O (0.023g, 0.05mmol), H2bpdc (0.024g, 0.10mmol) in distilled water (10mL) that adjusted the pH value to 5.5 with 0.5molL-1 NaOH aqueous solution was placed in a Teflon-lined stainless steel vessel (25mL), heated to 160C for 72h and then cooled to room temperature at a rate of 5C/h. The colorless crystalline product of 1 was obtained (yield: 35% based on H2bpdc)., 4479-74-7

The synthetic route of 4479-74-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Ren, Ya-Lan; Wang, Fei; Hu, Huai-Ming; Chang, Zhuguo; Yang, Meng-Lin; Xue, Ganglin; Inorganica Chimica Acta; vol. 434; (2015); p. 104 – 112;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

112881-51-3, 4′-(4-Pyridyl)-2,2′:6′,2”-terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Ru(1)Cl3 (0.10 g, 0.17 mmol) and ligand 3 (0.05 g, 0.17 mmol) was suspended in ethane-1,2-diol (8 cm3). The suspension heated at 150 C for 2 h. The deep red solution was poured into excess aqueous KPF6 (20 mL). A red precipitate formed and was collected on Celite, washed with H2O (5 mL), EtOH (2 mL), Et2O (5 mL), and dissolved in CH3CN. The product was purified by chromatography (SiO2, CH3CN:H2O:saturated aqueous KNO3 14:1.2:0.5). Addition of excess aqueous saturated KPF6 solution and removal of CH3CN under reduced pressure gave a red precipitate which was collected on Celite, washed with H2O (5 mL), EtOH (2 mL), Et2O (5 mL) and dissolved in CH3CN. Removal of solvent gave [Ru(1)(3)](PF6)2 as a red solid (74 mg, 68 mumol, 40%)., 112881-51-3

As the paragraph descriping shows that 112881-51-3 is playing an increasingly important role.

Reference£º
Article; Shen, Chao; Wang, Pi; Beves, Jonathon E.; Polyhedron; vol. 103; (2016); p. 241 – 247;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

Compound 45 (50 mg, 0.062 mmol) and (3-bromopropyl)- trimethylammonium bromide (162mg, 0.62 mmol, LOEQV.) are dissolved and potassium carbonate (128 mg, 0.93 mmol, 15 eqv. ) is suspended under argon in absolute DMF (30 ML) and the mixture is stirred at 55C for 12 h. The solvent is removed in vacuo at 50C and the residue re- dissolved in a little methanol and applied to a pad of silica (2 cm deep). The unreacted ammonium salts are washed off with methanol (LOOOML). The product is eluted with acetic acid: methanol: water (3: 2: 1 by vol.). The solvents are removed under reduced pressure and the product further purified by chromatography on a column (lOOg) of Sephadex LH-20 eluting with n-butanol: water: acetic acid (4: 5: 1 by vol. , upper phase). The solvents are removed under reduced pressure, the residue re-dissolved in a little methanol and the solution is passed through a short column of anion exchange resin (Amberlite IRC 400, chloride form) using methanol as eluent. After removal of solvent, the product is dried at high vacuum to give a violet solid. 1H-NMR : 6H (300MHZ, CD30D) : 0. 89 (t, 3H, 3J= 7.5 Hz), 1.18-1. 34 (m, LOH), 1.41 (bs, 2H), 1.73 (quint, 2H, 3J= 7.5 Hz), 2.30-2. 44 (m, 6H), 3,31 (bs, 27H), 3.65-3. 73 (m, 6H), 3.93 (t, 2H, 3J= 7.5 Hz), 4.25-4. 42 (m, 6H), 7.08 (d, 2H, 3J= 7.5 Hz), 7. 30 (d, 6H, 3J= 7.5 Hz), 7.93 (d, 2H, 3J= 7.5 Hz), 8.05 (d, 6H, 3J= 7.5 Hz), 8.94 (bs, 8H)

3779-42-8, The synthetic route of 3779-42-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10534-59-5, Tetrabutylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a stirred solution of (25,5 ?)-Lambda^- [(5-ieri-butoxycarbonylamino-lH-tetrazol-l-yl)acetyl]-7-oxo-6-oxy-l,6-diazabicyclo[3.2.1] octane-2-carbohydrazide (4.65 g, 1.5 mmol, product from Step 6) in dimethylformamide (30 ml) was added dimethylformamide sulfur trioxide complex (2.76 g, 1.8 mmol) in one portion at 0C under argon atmosphere. The reaction mass was stirred at the same temperature for 30 minutes and allowed to attain ambient temperature. The reaction was monitored by thin layer chromatography using mixture of chloroform and methanol (9: 1) as solvent. After complete consumption of starting material tetrabutyl ammonium acetate (5.42 g, 1.8 mmol) dissolved in 20 ml of water was added to it at 25-30 C under stirring. The reaction was monitored by thin layer chromatography using mixture of chloroform and methanol (9: 1) as solvent. After complete consumption of starting material the volatiles were removed under reduced pressure. The residue was partitioned between dichloromethane (200 ml) and water (100 ml). The water layer was separated and organic layer washed with water (100 ml). The organic extract was dried over anhydrous sodium sulfate and concentrated under reduced pressure to provide 7.8 g of tetrabutyl ammonium salt of (2S,5R)-6- (sulfooxy)-7-oxo-N’-(lH-tetrazol- l-ylacetyl)- l,6-diaza bicycle [3.2.1]octane-2-carbohydrazide in 82% yield. Analysis: 9.3 (M- l) for free acid; for Molecular weight: 631 and Molecular formula: CioHi3N807S. (400MHz, DMSO-d6): S 7.93 (s, 1H), 5.33 (s, 2H), 3.97 (bs, 1H), 3.83(m, 1H), 3.14-3.10 (m, 9H), 2.87(m, 1H), 2.11- 1.5 (m, 4H), 1.54 (m, 8H), 1.33- 1.24 (m, 8H), 0.93-0.89 (m, 12H)., 10534-59-5

The synthetic route of 10534-59-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; WOCKHARDT LIMITED; TADIPARTHI, Ravikumar; PATIL, Vijaykumar Jagdishwar; DEKHANE, Deepak; SHAIKH, Mohammad Usman; BIRAJDAR, Satish; DOND, Bharat; PATEL, Mahesh Vithalbhai; (100 pag.)WO2017/81615; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1662-01-7, 4,7-Diphenyl-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1662-01-7, General procedure: The formerly reported protocol for the preparation of complex Ru-Cl [1] was modified,as described below, and this modification was used also for the Os(II) analogue Os-Cl. Thestarting dimer [M(mu-Cl)(eta6-pcym)Cl]2 (0.10 mmol; M = Ru or Os) reacted with an excess (0.15mmol) of bphen in 5 mL of MeOH in a microwave reaction system (100 C, 1 min). Theobtained solutions were cooled to ambient temperature, and an excess of NH4PF6 (3.0 mmol)was added. The solvent volume was reduced after 15 min of stirring at ambient temperature,until the solid formed. The obtained chlorido complexes [Ru(eta6-pcym)(bphen)Cl]PF6 (Ru-Cl)and [Os(eta6-pcym)(bphen)Cl]PF6 (Os-Cl) were collected by filtration, washed (1 ¡Á 0.5 mL ofMeOH and 3 ¡Á 1 mL of diethyl ether) and dried under vacuum.

As the paragraph descriping shows that 1662-01-7 is playing an increasingly important role.

Reference£º
Article; Starha, Pavel; Travni?ek, Zden?k; Van?o, Jan; Dvo?ak, Zden?k; Molecules; vol. 23; 2; (2018);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

168646-54-6, 5,6-Diamino-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Under nitrogen protection,A solution of 5-bromo-1-phenylindole-2,3-dione (Intermediate a) (30.2 g, 0.1 mol) and 1,10-phenanthroline-5,6-diamine (Intermediate b ) (21.0 g, 0.1 mol) was added to 200 mL of absolute ethanol.The reaction was allowed to warm to 70-75 ¡ã C for 24 hours.Reaction is completed, cooled to room temperature after the direct suction filter,The filter cake was rinsed with absolute ethanol and the crude product was crystallized from dichloroethane / absolute ethanol to give a yellow solid,That is the intermediate c, the yield of 70percent.

168646-54-6, As the paragraph descriping shows that 168646-54-6 is playing an increasingly important role.

Reference£º
Patent; Wanrun Pharmaceutical Co., Ltd.; Zhang, Xueheng; Ju, Chengliang; Shi, Yu; Yang, Teng; Chi, Pengli; Yang, Hao; (17 pag.)CN106366083; (2017); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.167316-27-0,N-((1S,2S)-2-Amino-1,2-diphenylethyl)-4-methylbenzenesulfonamide,as a common compound, the synthetic route is as follows.

Under an atmosphere of argon, 134 mg (0.2 mmol) of [RuCl2(hexamethylbenzene)]2 147 mg (0.4 mmol) of (S,S)-TsDPEN, 183 mg (2.8 mmol ) of potassium hydroxide, 3 mL of methylene chloride, and 3 mL of water were placed in a 20 mL Schlenk tube and stirred at room temperature for 1 hour. The organic phase was washed with water several times, and sodium sulfate was then added to the organic phase to dry it. The organic phase was further dried with CaH2 and then filtered, the solvent was removed by distillation, and the residue was dried under vacuum. The violet crystals thus obtained were used directly in a reaction as a catalyst. By the same procedure as in Reference Example 1, Ru[(S,S)-Tsdpen] (1,2,3,4,5-pentamethylbenzene), Ru[(S,S)-Tsdpen] (1,2,4,5-tetramethylbenzene), Ru[(S,S)-Tsdpen] (1,3,5-trimethylbenzene), Ru[(S,S)-Tsdpen] (p-cymene), and Ru[(S,S)-Msdpen] (hexamethylbenzene) were synthesized. Furthermore, RuH[(R,R)-Tsdpen] (1,3,5-trimethylbenzene) was synthesized by carrying out the reaction of Reference Example 1 in 2-propanol.

167316-27-0, As the paragraph descriping shows that 167316-27-0 is playing an increasingly important role.

Reference£º
Patent; Kanto Kagaku Kabushiki Kaisha; EP1439159; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

62937-45-5, A solution of 5-(4-chlorophenyl)-2-{ [l-(2-chloropyridin-3-yl) H-l,2,4-triazol-3-yl]methyl}-4- [(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-l,2,4-triazol-3-one (Example 44A; 70.0 mg, 140 muiotaetaomicron) in ethanol (280 mu) was treated with D-prolinamide (160 mg, 1.40 mmol) and stirred overnight at reflux. The reaction mixture was diluted with methanol and purified by preparative HPLC (Method 4) affording 56.3 mg (70 % of th.) of the title compound. LC-MS (Method 2): Rt = 1.52 min; MS (ESIpos): m/z = 578.2 [M+H]+ -NMR (400 MHz, DMSO-d6) delta [ppm]: 8.80 (s, 1H), 8.19 (dd, 1H), 7.79-7.52 (m, 5H), 7.06 (br s, 1H), 6.95-6.71 (m, 3H), 5.18-5.02 (m, 2H), 4.48-4.21 (m, 2H), 4.06-3.78 (m, 2H), 2.77-2.58 (m, 2H), 2.04-1.87 (m, 1H), 1.75-1.42 (m, 3H).

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; COLLIN-KROePELIN, Marie-Pierre; KOLKHOF, Peter; NEUBAUER, Thomas; FUeRSTNER, Chantal; POOK, Elisabeth; WITTWER, Matthias, Beat; LUSTIG, Klemens; TINEL, Hanna; LINDNER, Niels; SCHIRMER, Heiko; (449 pag.)WO2019/81307; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

581-50-0,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.581-50-0,2,3′-Bipyridine,as a common compound, the synthetic route is as follows.

General procedure: Complexes 3-6 were prepared according to the following procedure:after stirring for 1 h a methanolic solution (20 mL) ofHindo (0.4 mmol, 143 mg) and KOH (0.4 mmol, 23 mg), the solutionwas added to a methanolic solution (5 mL) of NiCl26H2O(0.2 mmol, 47 mg) simultaneously with a methanolic solution(5 mL) of bipy (0.2 mmol, 31 mg) for 3, bipyam (0.2 mmol,34 mg) for 4, phen (0.2 mmol, 36 mg) for 5 and Hpko (0.4 mmol,79 mg) for 6. The resultant solution was stirred for 30 min andwas left to evaporate slowly. Light-green microcrystalline product of complex 4 (105 mg, 55%) was collected after two weeks. Anal. Calc. for [Ni(indo)2(bipyam)], 4 (C48H39Cl2N5NiO8) (MW = 943.48) C, 61.11; H, 4.17; N, 7.42 found: C, 60.98; H, 4.04; N, 7.31%. IR (KBr disk): numax, cm-1; nu(C=O)indo, 1678(vs); nuasym(CO2), 1590 (vs); nusym(CO2), 1414 (s); Deltanu(CO2) = 176 cm-1; rho(C-H)bipyam: 765 (m). UV-Vis: as Nujol mull, lambda(nm): 995 (sh), 657, 418 (sh), 324, 308 (sh); in DMSO, lambda(nm) (epsilon, M-1cm-1): 997 (sh) (20), 662 (60), 424 (sh) (230), 324 (12740), 293 (17020); 10Dq = 10030 cm-1, B = 573 cm-1, 10Dq/B = 17.5. mueff at room temperature = 3.25 BM. Soluble in CHCl3 and DMSO (LambdaM = 5 S¡¤cm2¡¤mol-1, in 1 mM DMSO solution).

581-50-0 2,3′-Bipyridine 11389, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Perontsis, Spyros; Tialiou, Alexia; Hatzidimitriou, Antonios G.; Papadopoulos, Athanasios N.; Psomas, George; Polyhedron; vol. 138; (2017); p. 258 – 269;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI